Drug Combination Details
| General Information of the Combination (ID: C76931) | |||||
|---|---|---|---|---|---|
| Name | Shikonin NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Osteosarcoma
[ICD-11: 2B51]
|
Investigative | [1] | ||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [2] | |||
|
Mantle cell lymphoma
[ICD-11: 2A85]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | microRNA 19a | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Raji | CVCL_0511 | EBV-related Burkitt lymphoma | Homo sapiens | ||
| Namalwa | CVCL_0067 | EBV-related Burkitt lymphoma | Homo sapiens | |||
| In-vivo Model | A mixture of 1*107 Namalwa cells and PBS was injected subcutaneously in the right oxter of each male non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice (4 weeks old). | |||||
| Experimental
Result(s) |
Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | ||
| MG-63 | CVCL_0426 | Osteosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
Shikonin promotes adriamycin-induced apoptosis by upregulating caspase 3 and caspase 8 in osteosarcoma. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | TAP1 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Down-regulation | ATP generation | ||||
| Induction | Loss of mitochondrial membrane potential | |||||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells. | |||||
